Patent ID: 7727519

Claim:
A method of treating hepatitis C virus (HCV) infection in a subject in need of such treatment, wherein the HCV infection exhibits primary or secondary resistance to treatment with alpha interferon, comprising administering a therapeutically effective amount of omega interferon protein to the subject, the administering selected from the group consisting of: (i) is at a controlled rate over time and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between 48 and 194 micrograms per week, between 23 and 388 micrograms per week, and between 23 and 623 micrograms per week, and (ii) is by injection and the therapeutically effective amount of omega interferon is an amount of omega interferon selected from the group consisting of between about 1 and about 210 micrograms per week and between about 22.5 and about 360 micrograms per week.